在雌性大鼠中,经过急性 olanzapine 治疗后,下丘脑 mu-opioid 受体表达的变化:对养行为的影响
Maiken Krogsbaek1, Nick Yao Larsen2, Anne M Landau3
1Core Centre for Molecular Morphology, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Journal of chemical neuroanatomy
|August 9, 2023
概括
第二代抗精神病药物如奥兰扎宾可以导致体重增加. 这项研究发现,奥兰扎在大鼠下丘脑中改变了阿片类受体表达,这可能解释了这些代谢副作用.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 第二代抗精神病药与显著的体重增加和代谢功能障碍有关.
- 片受体对抗剂正在被探索作为辅助疗法,以减轻这些副作用.
- 第二代抗精神病药物对中央阿片类受体表达的影响仍然在很大程度上不明.
研究的目的:
- 为了研究急性 olanzapine 治疗后雌性大鼠下丘脑中阿片类受体表达的早期变化.
- 为了确定 olanzapine 是否会改变关键的下丘脑核中的 kappa,mu 和 delta 类阿片类受体的 mRNA 和蛋白质水平.
主要方法:
- 在临床上相关的血度下,对雌性大鼠进行急性 olanzapine 管理.
- 定量空间 in situ 杂交和受体自辐射学以评估阿片类受体表达.
- 对五个下垂体区域的分析:副腹腔核,弧形核,腹中核,背中核和侧面下垂体.
主要成果:
- 在48小时后,olanzapine治疗导致体重增加,增加食物摄入量和血葡萄糖升高.
- 在弧形核中观察到mu阿片类受体可用性的显著增加.
- 在分析的下丘脑区域中,没有检测到阿片类受体mRNA或蛋白质水平的其他显著变化.
结论:
- 在治疗的早期阶段, olanzapine 会调节下丘脑的阿片类系统.
- 在弧形核中增加的类阿片受体可用性可能会导致奥兰扎宾的代谢副作用.
- 需要进一步的研究,以充分阐明阿片类药物信号在抗精神病药物诱导的体重增加中的作用.
相关概念视频
Opioid Receptors: Overview
1.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.0K
Regulation of Food Intake
280
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
280
Analgesia and Pain Management
657
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
657


